Ikatybant Ranbaxy

Icatibant, the active ingredient in Ikatybant Ranbaxy, is a bradykinin B2 receptor antagonist presented as a sterile aqueous solution for subcutaneous injection. It is used to treat hereditary angioedema caused by C1‑inhibitor deficiency, helping patients who experience recurrent swelling attacks of the skin, gastrointestinal tract, or airway.

GNH USA supplies Ikatybant Ranbaxy as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with support for regulatory documentation and cold‑chain logistics where required.

Icatibant is indicated for the treatment of hereditary angioedema, a bradykinin‑mediated swelling disorder. - Hereditary angioedema type I: Reduces frequency and severity of acute swelling episodes. - Hereditary angioedema type II: Provides rapid relief of airway and facial edema. - Acute hereditary angioedema attacks: Offers prompt symptom control during an attack.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient local edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate headache. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hypotension: sudden drop in blood pressure. - Angioedema of the face or throat unrelated to hereditary attacks. - Severe hypersensitivity reactions: rash, fever, or organ involvement.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications. - Patient assessment: confirm diagnosis of hereditary angioedema prior to use. - Allergy screening: avoid in individuals with known hypersensitivity to icatibant or formulation excipients. - Pregnancy: prescribe only if the potential benefit justifies any potential risk to the fetus. - Concomitant ACE inhibitors: monitor closely for additive bradykinin effects. - Renal or hepatic impairment: adjust monitoring as clinical condition warrants. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that influence the bradykinin pathway or hemodynamic status.

Major Interactions (Avoid): - ACE inhibitors: concurrent use can increase bradykinin levels and heighten the risk of angioedema. - Angiotensin receptor blockers (ARBs): may also augment bradykinin‑mediated effects.

Moderate Interactions (Monitor Closely): - Other bradykinin B2 receptor antagonists: combined effect may reduce therapeutic benefit. - C1‑inhibitor concentrates: concurrent use may alter clinical response. - Estrogen‑containing contraceptives: can increase frequency of hereditary angioedema attacks, requiring closer observation.